YIELD GROWTH Subsidiary Flourish Mushroom Labs Appoints

New Post Public Reply Private Reply Replies (0) Message Board
nlightn
308
YIELD GROWTH Subsidiary Flourish Mushroom Labs Appoints former Chairman of Johnson & Johnson, Jeff B. Smith as Chairman of the Board
Thu January 16, 2020

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2020) - The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) announces its subsidiary Flourish Mushroom Labs Inc. has appointed Jeff B. Smith as a director and as Chairman of the Board.

51549_image.jpg

Jeff B. Smith, Director and Chairman of Flourish Mushroom Labs

Jeff B. Smith was an executive for over 20 years at Johnson & Johnson Consumer Companies, the world's largest and most diversified healthcare company with worldwide sales of US$76 billion in 2017. His roles included Chief Transformation Officer, Group Chairman, Consumer North America and President, U.S. Skincare. Jeff served on the Johnson & Johnson's Group Operating Committee Executive.

In his role as Johnson & Johnson Company Group Chairman for Consumer North America, Jeff delivered strong organic growth, new growth levers, and oversaw several important strategic acquisitions including Vogue International LLC, La Lumière and Neostrata. His division represented more than 42% of global revenue delivering over US$6.5 billion in annual revenue with mid-single digit growth rates; spent over US$1 billion in marketing investment; delivered consistent market share gains and doubled the regional profitability.

Prior to acting as Chairman of Johnson & Johnson (JNJ), in 2011 Jeff was appointed President, U.S. Skincare in the newly formed North American region. Jeff had full P&L responsibility for the Baby (JOHNSON'S®, AVEENO®) and Beauty Care divisions (NEUTROGENA®, AVEENO®, CLEAN & CLEAR®, LUBRIDERM® and KORRES® Natural products) within the United States. As President of Johnson & Johnson's largest business unit, Jeff grew it from the 3rd largest skincare company to #1 in the U.S. over 3.5 years.

Jeff began his career with Johnson & Johnson Inc. Canada, progressing through a number of sales assignments, becoming Vice President Sales in 1997. Jeff became President U.S. Wound Care, and Worldwide Franchise Vice President, in 1999. In 2003, he was appointed President, Johnson & Johnson Inc., Canada and led the successful integration of Johnson & Johnson Inc., McNeil Consumer Healthcare and Pfizer Consumer Healthcare in 2008. Prior to Johnson & Johnson, he worked for Procter & Gamble in Vancouver, B.C. in various sales management positions. He is deeply committed to the safety and health of consumers, and serves on numerous industry boards, including the Board of Directors of the Personal Care Products Council.

Born and raised in Canada, Jeff holds an MBA from Edwards School of Business, University of Saskatchewan and a BA in Economics, University of Saskatchewan. He is married, has 2 children and lives in Toronto, Canada.

Jeff joins the Flourish board after acting as Chairman of the Yield Growth advisory board for approximately one year, a position he continues to hold.

Yield Growth management changes: Amy Frankel changes role and title at Yield Growth from VP, Licensing, General Counsel and Corporate Secretary to Corporate Secretary, General Counsel and Vice President, People, Tom Bond changes his role to Yield Growth advisor and is no longer a director of Yield Growth or Urban Juve, and Rick Huang joins the Yield Growth board of directors and the Urban Juve board of directors in addition to his role as CFO at Yield Growth and Flourish Mushroom Labs.

About Flourish Mushroom Labs Inc.

Flourish Mushroom Labs aims to be a leader in the fast-growing medicinal mushrooms market-and improve life by offering high-quality mushroom-infused products. Flourish Mushroom Labs is planning to build a psilocybin mushroom laboratory in Saint Vincent and the Grenadines and is conducting research into potentially therapeutic benefits of compounds found in psychedelic mushrooms. It has filed a U.S. patent application for the use of psilocybin to aid in weight loss and treat obesity, diabetes and to help prevent heart disease. Flourish Mushroom Labs is a majority owned subsidiary of The Yield Growth Corp.

About The Yield Growth Corp.

The Yield Growth Corp. develops and manufactures plant-based products and conducts research for plant-based therapeutics in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. It owns the cannabis wellness brands Urban Juve, Wright & Well and Jack n Jane. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, Skechers and Aritzia (ATZAF). Its all natural hemp skincare brand, Urban Juve, has signed agreements for distribution in Canada, Colombia, Brazil, Costa Rica, Panama, Argentina, El Salvador, Ecuador, Peru, Greece, Cyprus, Bulgaria, Romania and Serbia. Yield Growth's Wright & Well brands have manufactured a THC/CBD line of topical and edible products in Oregon and plan to launch a CBD from hemp topicals line in California in 2020. Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It has filed 13 patents to protect its extraction method and other intellectual property. Yield Growth earns revenue through multiple streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny White, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677

1-833-515-BOSS 1-833-515-2677

https://seekingalpha.com/pr/17750604-yield-gr...on-johnson

Better Plant Sciences Inc. (VEGGD) Stock Research Links

VEGGD Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hi3D Unlocks AI 3D Model for Open-Source Innovation

Updated Category News Views 3

A New Era in 3D Model Accessibility Unless you’ve been hiding under a rock, it’s hard to miss how digital terraforming has shifted gears. With Hi3D V1.0 opening its doors, the playing field's getting a major reshuffle. Or, as they say, the table is being set, and everyone's getting a seat. By letting loose production-validated AI tools, Hi3D is throwing down the...

Continue Reading
Unicycive's Stock Plunge: Fraud Suit and FDA Hurdles

Updated Category News Views 7

Unicycive's Tumultuous Journey Lately, it's been a rocky road for Unicycive Therapeutics, Inc., with their stock free-falling 39.1% in the span of a heartbeat on June 30, 2026. What sparked this nosedive? The FDA kicked back their revised New Drug Application for a kidney disease treatment yet again, spotlighting old manufacturing issues never nipped in the bud. Talk...

Continue Reading
NYC's Carriage Horse Ban: A New Era for Urban Welfare

Updated Category News Views 4

You've got to hand it to New York City—this isn't just another Tuesday twist. The City Council's decision to nix horse-drawn carriages is like throwing a wrench in an antique machine. It's a bold move in a concrete jungle that's constantly wearing new coats. Tradition vs. Welfare: The Crux For years, the idea of horses prancing down NYC streets seemed like a quaint nod...

Continue Reading
Basic Invite's Holiday Card Service Offers Saving Time

Updated Category News Views 1

Getting the Cards Out: Maneuvering the Holiday Hustle Alright, let's dive into the madness that is holiday card season. Could be a logistical nightmare or a nostalgic tradition, depending on your cup of tea. Basic Invite here is trying to cut through the chaos by bumping deadlines and offering some straight-out-the-gate mailing options. If you play your cards right—pun...

Continue Reading
D-Wave Investors Face Pressure Ahead of December 15

Updated Category News Views 3

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Continue Reading
Celebrating Alexander Trost: A Lifetime of Compassionate Care

Updated Category News Views 4

A Legendary Career in Palliative Medicine You know, in a world where people glamorize stock flips and flashy earnings, it's refreshing to spotlight good old-fashioned compassion. Enter Dr. Alexander Trost, DNP, FNP-C, ACHPN. This fella has just been honored as a Pinnacle Lifetime Member by The Inner Circle—a nod to his impactful work in palliative medicine. You ever try...

Continue Reading
Tigo Energy Faces Class Action Over Revenue Claims

Updated Category News Views 3

Trouble Brewing for Tigo Energy? Straight from the horse's mouth, we hear about Tigo Energy (NASDAQ: TYGO) getting embroiled in a class action smackdown. Picture it: Tigo fumbles their projections, and boy does it sting. They're caught in the crossfire for allegedly puffing up their revenue expectations tied to a venture with EG4 Electronics—poised to churn out...

Continue Reading
Rising Food Safety Stars Honored: A Global Effort

Updated Category News Views 2

Food Safety Breakthrough: Youth Leads the Charge When it comes to food safety, it’s about time the younger crowd gets their due. The latest crew to step up to the plate is the Class of 2026's 40 Under 40 Food Safety Professionals. They’re not just pushing paper; these folks are setting the bar high and innovating across continents with real, tangible changes. From...

Continue Reading
Ellington's Q3 Earnings Call: What Investors Need to Know

Updated Category News Views 5

An Anticipated Unveiling Ellington Financial Inc. (NYSE:EFC) is gearing up to spill the beans on its third-quarter financials for 2026. It's all going down after the markets close on November 4th. I can tell you, folks, anyone keeping an eye on EFC will be itching to know what's inside those numbers. With a company this deep into financial assets, reading between the...

Continue Reading
Dott's Q3 2026: Micromobility Growth Soars High

Updated Category News Views 5

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...

Continue Reading

Top 5 Most Recently Viewed Articles

ComFree's Remarkable Comeback: A New Era in Real Estate

Updated Category News Views 375

ComFree's Return to the Market After a notable absence, ComFree is back, igniting excitement in the real estate industry. The company's founders, Erin and Travis Holowach, originally created ComFree as a platform for homeowners to sell properties without agent interference, saving them significant fees. Their mission is now revitalized as they reclaim the brand they built...

Continue Reading
Why Capital Gains Tax Planning Matters for Long-Term Investors

Updated Category Investing Views 159

The average federal income tax paid by a typical person ranges from 13.5% to 15%, and tax planning is a mathematical necessity for anyone serious about building long-term wealth in the United States. Every dollar lost to an inefficient exit from an investment is a dollar that stops compounding for your future self. There are thousands of taxable events triggered daily...

Continue Reading
Biomea Fusion Reports Milestone 52-Week Findings in Diabetes

Updated Category News Views 164

Biomea Fusion Unveils Promising Efficacy of Icovamenib Biomea Fusion, Inc. (Nasdaq: BMEA), a pioneer in clinical-stage advancements for diabetes and obesity, recently announced significant 52-week results from its Phase II COVALENT-111 study. This study examined the potential effects of icovamenib, a novel treatment for type 2 diabetes (T2D), and the results underscore a...

Continue Reading
D-Wave Hit with Legal Scrutiny After Disappointing Q2

Updated Category News Views 23

D-Wave Quantum Under Legal Microscope Alright, folks, let's dive headfirst into some dicey financial waters with D-Wave Quantum Inc. (NASDAQ: QBTS). This quantum computing company is finding itself in a bit of a pickle following some rough second-quarter results that left investors scratching their heads. If you bought into the hype and are feeling the sting in your...

Continue Reading
Groundbreaking Debut of DeriW Exchange at Exclusive Event

Updated Category News Views 309

Groundbreaking Launch of DeriW Exchange DeriW, an innovative decentralized perpetual exchange, has officially launched during an exclusive event, showcasing its advanced features and capabilities. The event, hosted by CoinW, attracted 400 influential figures from the cryptocurrency sector. Among the attendees were thought leaders, blockchain pioneers, and affiliates, all...

Continue Reading